Literature DB >> 16971443

Multivalent sequence recognition by Epstein-Barr virus Zta requires cysteine 171 and an extension of the canonical B-ZIP domain.

Pu Wang1, Latasha Day, Paul M Lieberman.   

Abstract

Epstein-Barr virus (EBV) immediate-early protein Zta is a member of the basic-leucine zipper (B-ZIP) family of DNA binding proteins that has an unusual capacity to recognize multiple DNA recognition sites, including AP-1 and C/EBP binding sites. To better understand the structure and function of Zta, we have mutagenized cysteine residues within or adjacent to the B-ZIP domain. We found that serine substitution for cysteine 171 (C171S), which lies outside and amino terminal to the B-ZIP basic region, completely abrogates Zta capacity to initiate lytic cycle replication. C171S disrupted Zta transcription activation function of several EBV lytic cycle promoters, including the BMRF1 gene (EA-D) and the other lytic activator, Rta. Overexpression of Rta could not rescue the C171S defect for transcription reactivation or viral DNA replication. Zta C171S was defective for binding to these promoters in vivo, as measured by chromatin immunoprecipitation assay. Purified Zta C171S bound AP-1 sites similar to wild-type Zta, but it was incapable of binding several degenerate Zta sites, including a consensus C/EBP site. Zta truncation mutations reveal that residues N terminal to the B-ZIP (amino acids 156 to 178) confer C/EBP binding capacity to the otherwise AP-1-restricted DNA recognition function. Comparison among viral orthologues of Zta suggest that a conserved N-terminal extension of the consensus B-ZIP domain is required for this multivalent DNA recognition capacity of Zta and is essential for viral reactivation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16971443      PMCID: PMC1642168          DOI: 10.1128/JVI.00907-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators.

Authors:  R Feederle; M Kost; M Baumann; A Janz; E Drouet; W Hammerschmidt; H J Delecluse
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

2.  Lytic but not latent replication of epstein-barr virus is associated with PML and induces sequential release of nuclear domain 10 proteins.

Authors:  P Bell; P M Lieberman; G G Maul
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  The EBV lytic switch protein, Z, preferentially binds to and activates the methylated viral genome.

Authors:  Prasanna M Bhende; William T Seaman; Henri-Jacques Delecluse; Shannon C Kenney
Journal:  Nat Genet       Date:  2004-09-12       Impact factor: 38.330

4.  Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA.

Authors:  J Countryman; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

5.  Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion.

Authors:  J S Greenspan; D Greenspan; E T Lennette; D I Abrams; M A Conant; V Petersen; U K Freese
Journal:  N Engl J Med       Date:  1985-12-19       Impact factor: 91.245

6.  Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies.

Authors:  A L Adamson; S Kenney
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

7.  Interaction with the Epstein-Barr virus helicase targets Zta to DNA replication compartments.

Authors:  G Liao; F Y Wu; S D Hayward
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

8.  Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma.

Authors:  R Dardari; M Khyatti; A Benider; H Jouhadi; A Kahlain; C Cochet; A Mansouri; B El Gueddari; A Benslimane; I Joab
Journal:  Int J Cancer       Date:  2000-04-01       Impact factor: 7.396

9.  Identification of acidic and aromatic residues in the Zta activation domain essential for Epstein-Barr virus reactivation.

Authors:  Z Deng; C J Chen; D Zerby; H J Delecluse; P M Lieberman
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 10.  Integration and diversity of the regulatory network composed of Maf and CNC families of transcription factors.

Authors:  Hozumi Motohashi; Tania O'Connor; Fumiki Katsuoka; James Douglas Engel; Masayuki Yamamoto
Journal:  Gene       Date:  2002-07-10       Impact factor: 3.688

View more
  5 in total

1.  Evidence for DNA hairpin recognition by Zta at the Epstein-Barr virus origin of lytic replication.

Authors:  Andrew J Rennekamp; Pu Wang; Paul M Lieberman
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

2.  A Noncanonical Basic Motif of Epstein-Barr Virus ZEBRA Protein Facilitates Recognition of Methylated DNA, High-Affinity DNA Binding, and Lytic Activation.

Authors:  Erin Weber; Olga Buzovetsky; Lee Heston; Kuan-Ping Yu; Kirsten M Knecht; Ayman El-Guindy; George Miller; Yong Xiong
Journal:  J Virol       Date:  2019-06-28       Impact factor: 5.103

3.  The Epstein-Barr virus BZLF1 protein inhibits tumor necrosis factor receptor 1 expression through effects on cellular C/EBP proteins.

Authors:  Jillian A Bristol; Amanda R Robinson; Elizabeth A Barlow; Shannon C Kenney
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

4.  Epstein-Barr virus immediate-early protein Zta co-opts mitochondrial single-stranded DNA binding protein to promote viral and inhibit mitochondrial DNA replication.

Authors:  Andreas Wiedmer; Pu Wang; Jing Zhou; Andrew J Rennekamp; Valeria Tiranti; Massimo Zeviani; Paul M Lieberman
Journal:  J Virol       Date:  2008-02-27       Impact factor: 5.103

5.  A subset of replication proteins enhances origin recognition and lytic replication by the Epstein-Barr virus ZEBRA protein.

Authors:  Ayman El-Guindy; Lee Heston; George Miller
Journal:  PLoS Pathog       Date:  2010-08-19       Impact factor: 6.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.